Helsinn has agreed to acquire worldwide rights to Valchlor/Ledaga (mechlorethamine/chlormethine), an alkylating agent for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL), from Actelion Pharmaceuticals.
Cipher Pharmaceuticals has entered into a definitive arrangement agreement to acquire the Canadian business portfolio of Cardiome Pharma.
Researchers from European Molecular Biology Laboratory (EMBL) have revealed that one in four drugs with human targets could affect the growth of bacteria in the human gut.
Biogen and AbbVie are withdrawing their multiple sclerosis (MS) drug Zinbryta (daclizumab) from global market after reports of eight cases of serious brain inflammation.
French drugmaker Sanofi has agreed to acquire US-based biotechnology firm Bioverativ for about $11.6bn.
Cell and Gene Therapy (CGT) Catapult and Sweden-based CombiGene have signed an agreement to develop manufacturing process for novel gene therapy to treat epilepsy.
A new partnership between Regeneron Pharmaceuticals and five other drug manufacturers intends to accelerate the generation of genetic exome sequence data from the 500,000 participants of the UK Biobank.
Researchers at Cardiff University in the UK have developed a new method to test the likelihood of a drug turning into a potentially harmful version of itself when it enters the body.
ANI Pharmaceuticals has acquired the new drug applications (NDAs) and US marketing rights for AstraZeneca’s Atacand, Atacand HCT, Arimidex, and Casodex for $46.5m.
Mallinckrodt has signed a deal to acquire US-based Sucampo Pharmaceuticals for about $1.2bn to add the latter’s constipation medication Amitiza (lubiprostone) and other commercial and development assets to its portfolio.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.